Experimental cell therapy takes aim at Hard-to-Treat cancers

NCT ID NCT06001684

Completed Disease control Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion twice per treatment cycle. The study will also look for early signs that the therapy might shrink or control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBR854 cell injection
What this could lead to: If successful, this could point toward a new cell-based treatment option for people with advanced solid tumors that have limited alternatives.
What could go wrong: This is an early phase 1 trial with only 19 participants, so safety and effectiveness are not yet established. Cell therapies can cause serious side effects, and the treatment may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.